A phase I dose escalation study of ABI-007 [paclitaxel] with carboplatin as first-line therapy in patients with epithelial ovarian, primary peritoneal or fallopian tube carcinoma.
Latest Information Update: 22 Oct 2019
Price :
$35 *
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Abraxis BioScience; Celgene Corporation
- 02 Feb 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 12 Dec 2006 New trial record.